Sanofi's Vaccines Performance Helps Offset Diabetes Decline

Performance of Dupixent, which just picked up a new indication, was a third quarter highlight and bodes well for future growth, but sales of the blockbuster insulin glargine Lantus are crumbling.

Lyon France, 3 October 2017: White logo of the french multinational pharmaceutical company Sanofi on their glass office building in Lyon France

Sanofi touted the promise of new launches and a return to growth in the third quarter, which helped offset the continued decline of its top-selling, but now genericized, Lantus (insulin glargine).

The company reported third quarter sales of €9.4bn ($8.3bn) on Oct. 31, which was up 6.3% year-over-year and beat the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business